Destiny Pharma plc

Equities

DEST

GB00BDHSP575

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:03 2024-04-26 am EDT			5-day change	1st Jan Change
16.25 ^GBX	-2.99%		-23.53%	-76.79%

Apr. 25	Norcros sells Johnson Tiles UK; Trifast trading well	AN
Apr. 25	Transcript : Destiny Pharma plc, 2023 Earnings Call, Apr 25, 2024

Destiny Pharma upbeat on prospects for C. Difficile treatment

April 06, 2023 at 09:55 am EDT

(via NewsDirect)

Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) chief scientific officer Bill Love speaks to Proactive after results from a study into its C. Difficile treatment platform NTCD-M3 were published in the Microbiology Spectrum journal.

Love explains what makes the platform so promising from Destiny's point of view, before going on to reveal more about the plans for bringing NTCD-M3 to the market.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Latest news about Destiny Pharma plc

Norcros sells Johnson Tiles UK; Trifast trading well	Apr. 25	AN
Transcript : Destiny Pharma plc, 2023 Earnings Call, Apr 25, 2024	Apr. 25
AIM WINNERS & LOSERS: Kromek jumps 14% on US government contract	Apr. 25	AN
Destiny Pharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
EARNINGS AND TRADING: STV raises holding in Two Cities Television	Jan. 31	AN
Destiny Pharma to Advance Skin, Colon Infection Therapies After Positive Evaluations	Jan. 31	MT
Destiny Pharma plc Announces Clinical Development Update Positive Results from XF-73 Dermal Safety Study	Jan. 31	CI
Destiny Pharma seeks to capitalise on XF-73 market potential in 2024	Jan. 04	AN
Destiny Pharma Says Talks Ongoing with Potential Partners for Nasal Asset	Jan. 04	MT
Destiny Pharma celebrates study findings on "potent" flagship drug	23-10-17	AN
AIM WINNERS & LOSERS: Destiny Pharma posts "landmark" XF-73 data	23-10-17	AN
Destiny Pharma plc Announces the Publication of New Microbiological Data on Xf-73 (Exeporfinium Chloride), Its Leading Antibacterial Drug,In Frontiers in Cellular and Infection Microbiology	23-10-17	CI
Dianomi swings to loss; Epwin revenue up	23-09-20	AN
Earnings Flash (DEST.L) DESTINY PHARMA Reports H1 Loss GBX-3.10	23-09-20	MT
Destiny Pharma plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-20	CI
MGC Pharmaceuticals granted psilocybin import permit	23-07-31	AN
Destiny Pharma plc Announces the Publication of New Data in the Journal Infection & Drug Resistance from A Study Evaluating the Pfficacy of Xf-73	23-07-31	CI
FTSE 100 Closes Tuesday Up 0.2% Lifted by Unilever, Miners	23-07-25	DJ
Destiny Pharma says former Chair Nigel Rudd return to role	23-07-25	AN
Former Destiny Pharma Chairman Reprises Role	23-07-25	MT
Destiny Pharma plc Appoints Sir Nigel Rudd as New Chairman	23-07-25	CI
FTSE 100 Rose 1.8% Led by Housebuilders on Signs of Slowing UK Inflation	23-07-19	DJ
UK Corporate Credit Distress Likely to Rise	23-07-19	DJ
Destiny Pharma Welcomes New CEO; Chair Steps Down	23-07-19	MT
Destiny Pharma appoints Chris Tovey as CEO; Chair resigns	23-07-19	AN

Chart Destiny Pharma plc

Duration

Period

More charts

Company Profile

Destiny Pharma plc is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of novel medicines that can prevent life-threatening infections. The Company's drug development pipeline includes two late stage assets, NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.difficile infection (CDI) recurrence, which is the principal cause of hospital acquired infection in the United States, and XF-73 nasal gel, a proprietary drug targeting the prevention of postsurgical staphylococcal hospital infections including methicillin-resistant Staphylococcus aureus (MRSA). The Companyâs earlier stage pipeline is focused on other indications including two, separate dermal programmes incorporating its XF platform. It is also collaborating with SporeGen on a novel SPOR-COV innate immune system boosting nasal spray for the prevention of COVID-19 and influenza.

Sector

Biotechnology & Medical Research

Calendar

2024-09-18 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.1625 GBP

Average target price

1.933 GBP

Spread / Average Target

+1,089.74%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DESTINY PHARMA PLC	-76.79%	19.29M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs